Patient Support Programs
Week ending September 27, 2026
1. Self-management questions this week
10 questions / 65 answer variants were monitored; the most relevant to PSP operations were:
- Dosing schedule and titration: One question with 7 responses asked, “What is the recommended starting dose…how do I increase it, and how often should I inject it?” Answers consistently described a 0.25 mg once-weekly starter dose for four weeks, but varied in how much they emphasized confirming the prescribed pen and schedule.
- Missed doses: One question with 7 responses asked whether to “skip it or take it later?” This is the clearest adherence-related theme this week.
- Side-effect/condition management: Questions covered what to do with possible pancreatitis, kidney disease or worsening renal function, and hypoglycemia risk with insulin or sulfonylureas. The pancreatitis answers generally advised stopping/holding Ozempic and seeking urgent evaluation.
- Injection technique, storage/handling, and everyday coping with common side effects: No direct questions were tagged this week. This is absence of observed demand, not evidence that patients do not need these materials.
2. Where guidance is inconsistent or thin
The priority inconsistency is missed-dose guidance. Responses split between a 48-hour window—“if it’s been less than 48 hours”—and a five-day window—“within 5 days.” Several also use less actionable wording such as “if it’s close to your next scheduled dose.” This could lead to delayed, premature, or duplicate dosing. The onboarding guide, reminder messages, and hotline script should use one approved, plain-language rule.
Other inconsistencies are lower priority but relevant to coaching:
- Kidney-disease answers variably mention hypoglycemia, despite the practical focus being dehydration from nausea/vomiting/poor intake.
- Pancreatitis responses vary between “stop the next dose” and “stop immediately,” although they consistently direct urgent evaluation.
- Across the dataset, 50 of 65 responses included hedging/disclaimer language. On practical questions, repeated “ask your prescriber” or “tell me more” can leave patients without a clear next step.
3. Support-pathway visibility
Some responses point patients to a prescriber, pharmacist, urgent care, or emergency evaluation. However, none visibly connect patients to a nurse educator, PSP hotline, injection-training resource, or structured support pathway. General AI assistants cannot know our program; this is therefore a structural gap for PSP onboarding and follow-up. Patients may be left to resolve dosing questions alone.
4. Trend across weeks
Volume is broadly steady at the recent lower level: 10 questions/65 responses, versus 9/63 last week. Inconsistency flags improved from 20 to 16, but remain material. Dosing-related content fell slightly (28 to 26), while hypoglycemia rose (24 to 29) and pancreatitis rose (27 to 29). Missed-dose inconsistency remains the most actionable issue.
5. Recommended actions
- Update missed-dose onboarding and hotline scripts with one approved rule; explicitly address “48 hours versus 5 days” and “do not double dose.”
- Add a visible PSP escalation path to onboarding, reminders, and AI-facing web content: nurse line/support coordinator for dosing, administration, and side-effect questions.
- Create a concise dose/titration teach-back checklist covering weekly timing, prescribed pen strength, and when not to self-adjust.
- Reinforce kidney/GI guidance with practical hydration and escalation prompts; coordinate severe pancreatitis wording with Medical Information/PV as appropriate.